# Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART

> **NCT02249962** · — · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 12011 (actual)

## Conditions studied

- HIV
- Infant Exposure to Efavirenz

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02249962
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 12011 (ACTUAL)
- **Last updated:** 2021-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249962, "Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02249962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*